<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
     xmlns:media="http://search.yahoo.com/mrss/"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:wfw="http://wellformedweb.org/CommentAPI/"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:atom="http://www.w3.org/2005/Atom"
     xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
     xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
    xmlns:company="http:/purl.org/rss/1.0/modules/company" xmlns:fool="https://fool.com/rss/extensions"     >

    <channel>
        <title>Radiopharm Theranostics (ASX:RAD) Share Price News | The Motley Fool Australia</title>
        <atom:link href="https://www.fool.com.au/tickers/asx-rad/feed/" rel="self" type="application/rss+xml" />
        <link>https://www.fool.com.au/tickers/asx-rad/</link>
        <description>Since 1993, millions of investors have trusted The Motley Fool for simple, down-to-earth investing research.</description>
        <lastBuildDate>Fri, 20 Nov 2026 23:12:51 +0000</lastBuildDate>
        <language>en-AU</language>
                <sy:updatePeriod>hourly</sy:updatePeriod>
                <sy:updateFrequency>1</sy:updateFrequency>
        <generator>https://wordpress.org/?v=7.0.9</generator>

<image>
	<url>https://www.fool.com.au/wp-content/uploads/2020/06/cropped-cap-icon-freesite-96x96.png</url>
	<title>Radiopharm Theranostics (ASX:RAD) Share Price News | The Motley Fool Australia</title>
	<link>https://www.fool.com.au/tickers/asx-rad/</link>
	<width>32</width>
	<height>32</height>
</image> 
<atom:link rel="hub" href="https://pubsubhubbub.appspot.com"/>
<atom:link rel="hub" href="https://pubsubhubbub.superfeedr.com"/>
<atom:link rel="hub" href="https://websubhub.com/hub"/>
<atom:link rel="self" href="https://www.fool.com.au/tickers/asx-rad/feed/"/>
            <item>
                                <title>This biotechnology stock just ticked over 100% gains for the month on more good news</title>
                <link>https://www.fool.com.au/2025/09/30/this-biotechnology-stock-just-ticked-over-100-gains-for-the-month-on-more-good-news/</link>
                                <pubDate>Tue, 30 Sep 2025 03:34:30 +0000</pubDate>
                <dc:creator><![CDATA[Cameron England]]></dc:creator>
                		<category><![CDATA[Healthcare Shares]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1806573</guid>
                                    <description><![CDATA[<p>Two drug development agreements in under a month have caused this junior biotech's shares to surge.</p>
<p>The post <a href="https://www.fool.com.au/2025/09/30/this-biotechnology-stock-just-ticked-over-100-gains-for-the-month-on-more-good-news/">This biotechnology stock just ticked over 100% gains for the month on more good news</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>Starpharma Holdings Ltd </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-spl/">ASX: SPL</a>) shareholders are sitting on gains of more than 100% for the month after the company announced a new collaboration with <strong>Radiopharm Theranostics Ltd </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rad/">ASX: RAD</a>).</p>



<p class="wp-block-paragraph">The junior biotechnology company's stock was up 13.6% in early trade to 25 cents, compared with the closing price of 12 cents at the start of September. </p>



<p class="wp-block-paragraph">And over a 12-month period, the gains are even more impressive, with the low over the past year being 8.2 cents per share.</p>



<p class="wp-block-paragraph">Starpharma said on Tuesday it had signed a research and option agreement with Radiopharm following six months of preliminary research.</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">Starpharma will apply its proprietary DEP platform technology to develop and manufacture a dendrimer-drug conjugate that incorporates a radiopharmaceutical molecule under development by Radiopharm. Starpharma will receive R&amp;D service and manufacturing fees for this phase of work, with activities to commence immediately.</p>
</blockquote>



<p class="wp-block-paragraph">Under the licence agreement, Starpharma is eligible to receive a $500,000 option fee, a $2 million upfront payment, and up to $89 million in success-based milestones and royalties on net sales.</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">This agreement marks a key milestone for Starpharma as the company's first radiopharmaceutical partnership and the first Star Navigator program to advance into a formal research collaboration.</p>
</blockquote>



<h2 class="wp-block-heading" id="h-second-dose-of-good-news-this-month">Second dose of good news this month</h2>



<p class="wp-block-paragraph">The Radiopharm agreement follows another deal Starpharma struck with major drug company Genentech, which was announced earlier in September.</p>



<p class="wp-block-paragraph">Under that deal, which had been in the works for three years, Starpharma was in line for success payments of up to US$564 million ($857.4 million).</p>



<p class="wp-block-paragraph">Starpharma&nbsp;<a href="https://www.fool.com.au/investing-education/healthcare-shares/">specialises in "dendrimer" technology</a>, which involves manufacturing nanoscale molecules for use in pharmaceutical applications.</p>



<p class="wp-block-paragraph">Starpharma Chief Executive Officer Cheryl Maley said on Tuesday that the Radiopharm deal was a key milestone for the company and provided external validation for the potential of dendrimers in the area of radiopharmaceutical drug development.</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">Radiopharmaceuticals are a key area of focus for Starpharma. Our strategy involves developing high-value, differentiated assets and forming strategic partnerships, all supported by robust scientific data. Over the past 12 months Starpharma has worked diligently to optimise our internal DEP radiotheranostics program, while actively showcasing the unique capabilities of dendrimers at high-profile scientific conferences. These events have generated industry interest and opened new avenues for collaboration.</p>
</blockquote>



<p class="wp-block-paragraph">Radiopharm Theranostics Chief Executive Officer Riccardo Canevari stated that the targeted radiotherapeutic sector is evolving rapidly.</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">We are committed to exploring different and innovative options, which have the potential to improve the efficacy and the safety of new radiopharmaceutical vectors. We are excited by the opportunity to work with the capable team of Starpharma to pursue this important and ambitious goal.</p>
</blockquote>



<p class="wp-block-paragraph">Radiopharm Theranostics shares were 3.4% lower at 2.8 cents.</p>
<p>The post <a href="https://www.fool.com.au/2025/09/30/this-biotechnology-stock-just-ticked-over-100-gains-for-the-month-on-more-good-news/">This biotechnology stock just ticked over 100% gains for the month on more good news</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>2 ASX small-cap shares rocketing 35% to 54% today</title>
                <link>https://www.fool.com.au/2025/01/10/2-asx-small-cap-shares-rocketing-35-to-54-today/</link>
                                <pubDate>Fri, 10 Jan 2025 01:08:00 +0000</pubDate>
                <dc:creator><![CDATA[Bernd Struben]]></dc:creator>
                		<category><![CDATA[Share Gainers]]></category>
		<category><![CDATA[Small Cap Shares]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1768718</guid>
                                    <description><![CDATA[<p>Two soaring ASX small-cap shares are setting the bar high on Friday.</p>
<p>The post <a href="https://www.fool.com.au/2025/01/10/2-asx-small-cap-shares-rocketing-35-to-54-today/">2 ASX small-cap shares rocketing 35% to 54% today</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph">The first full trading week of 2025 is ending on a high note for stockholders of two rocketing ASX small-cap shares.</p>



<p class="wp-block-paragraph">How high?</p>



<p class="wp-block-paragraph">Well, shares in rare earths and nickel-focused resource explorer Aldoro Resources Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-arn/">ASX: ARN</a>) were up 34.5% in early trade on Friday at 39 cents apiece. After some likely profit-taking, shares are changing hands for 33 cents each at the time of writing, up 14%.</p>



<p class="wp-block-paragraph">And investors in ASX small-cap share <strong>Radiopharm Theranostics Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rad/">ASX: RAD</a>) will really be cheering today. In earlier trade shares in the clinical-stage biopharmaceutical company reached highs of 3.7 cents, up 54.2%. They're currently trading for 3.5 cents apiece, up 45.8%.</p>



<p class="wp-block-paragraph">Here's what's stoking investor interest today.</p>



<h2 class="wp-block-heading" id="h-asx-small-cap-shares-soar-on-promising-updates"><strong>ASX small-cap shares soar on promising updates</strong></h2>



<p class="wp-block-paragraph">Turning to Aldoro Resources first, investors are piling into the ASX small-cap share after the explorer <a href="https://www.fool.com.au/tickers/asx-arn/announcements/2025-01-10/6a1246541/exceptional-uninterrupted-niobium-strike-mineralisation/">reported</a> on assays confirming an "exceptional uninterrupted niobium strike" at its Kameelburg project, located in Namibia.</p>



<p class="wp-block-paragraph">Following strong results reported in December, Aldoro said the assays it received for the remainder of Line 3 confirmed that the entire 388 meters of the line was mineralised with niobium and appeared open in both directions.</p>



<p class="wp-block-paragraph">The niobium grade across the entire line was confirmed to be 0.52% Nb2O5.</p>



<p class="wp-block-paragraph">Also likely spurring investor excitement, the company said that an additional 4,500 meters of trench sampling were awaiting assay, with rare earths mineralisation previously discovered along this line.</p>



<p class="wp-block-paragraph">Moving on to Radiopharm Theranostics, the ASX small-cap share is shooting the lights out today after announcing it has executed a subscription agreement for a private share placement to United States-based radiopharmaceutical-focused company Lantheus Holdings.</p>



<p class="wp-block-paragraph">Management noted that the placement of 133 million shares was completed at an issue price of 6 cents per share, a 150% premium to the last traded share price of 2.4 cents per share.</p>



<p class="wp-block-paragraph">The company expects the settlement of $8.0 million capital raising to occur within seven days.</p>



<p class="wp-block-paragraph">Commenting on the deal sending the ASX small-cap share rocketing today, Radiopharm Theranostics CEO Riccardo Canevari said: "We are delighted to have Lantheus increase its shareholding in RAD, now making it the largest shareholder with over 12% of the company."</p>



<p class="wp-block-paragraph">Canevari continued:</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">We have been working closely with Lantheus since the initial investment announced in June 2024, and we are delighted with the collaboration that has been taking place between our two companies. We look forward to continuing this positive momentum going forward.</p>
</blockquote>



<p class="wp-block-paragraph">Lantheus CEO Brian Markison added, "We are pleased to increase our holding in Radiopharm, while continuing to work jointly in Australia on the clinical development of radiopharmaceutical assets."</p>
<p>The post <a href="https://www.fool.com.au/2025/01/10/2-asx-small-cap-shares-rocketing-35-to-54-today/">2 ASX small-cap shares rocketing 35% to 54% today</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>&#039;Richest pipeline&#039; in ASX: Expert names 3 small-cap shares to buy</title>
                <link>https://www.fool.com.au/2022/07/28/richest-pipeline-in-asx-expert-names-3-small-cap-shares-to-buy/</link>
                                <pubDate>Wed, 27 Jul 2022 21:30:00 +0000</pubDate>
                <dc:creator><![CDATA[Tony Yoo]]></dc:creator>
                		<category><![CDATA[Ask a Fund Manager]]></category>
		<category><![CDATA[Small Cap Shares]]></category>
		<category><![CDATA[editor's choice]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1414608</guid>
                                    <description><![CDATA[<p>Ask A Fund Manager: Alto Capital's Tony Locantro also reveals what his biggest regret in investing is.</p>
<p>The post <a href="https://www.fool.com.au/2022/07/28/richest-pipeline-in-asx-expert-names-3-small-cap-shares-to-buy/">&#039;Richest pipeline&#039; in ASX: Expert names 3 small-cap shares to buy</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<h2 class="wp-block-heading" id="h-ask-a-fund-manager">Ask A Fund Manager</h2>



<p class="wp-block-paragraph"><em>The Motley Fool chats with the best in the industry so that you can get an insight into how the professionals think. In this edition, Alto Capital investment advisor Tony Locantro talks about why he loves three ASX shares in particular and his biggest regret in investing.</em></p>



<h3 class="wp-block-heading" id="h-cut-or-keep">Cut or keep?</h3>



<p class="wp-block-paragraph"><strong>The Motley Fool:</strong> You've mentioned <strong>Radiopharm Theranostics Ltd </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rad/">ASX: RAD</a>) in the past, but it has now dropped about 40% year-to-date. How do you feel about it now? Would you still buy it?</p>



<p class="wp-block-paragraph"><strong>Tony Locantro:</strong> Yeah, it was one of the first to lift its head off the canvas during tax loss selling. It was a 60 cent <a href="https://www.fool.com.au/definitions/initial-public-offering/">IPO</a> that was poorly supported &#8212; fell to a ridiculous low of 13 cents during the last week of tax loss selling. It's since recovered to 23 cents.&nbsp;</p>



<p class="wp-block-paragraph">It is in radiopharmaceuticals. They've also added brain tumour technology. It has one of the richest pipelines of any ASX by a technology company, with multiple phase one trials for the remainder of this year and multiple trials next year.</p>



<p class="wp-block-paragraph">I have bought heavily personally. I am currently underwater and really need to see the stock recover. It has been building a world-class management team, but the stock just fell out of favour as the <strong>Nasdaq Composite</strong> (INDEXNASDAQ: .IXIC) and US biotech indices underwent a significant correction.&nbsp;</p>



<p class="wp-block-paragraph">So the answer to that is yes, it is still great value, but was even better value a few weeks ago… No change to the fundamental view or my faith in management or the company.</p>



<h3 class="wp-block-heading" id="h-the-asx-share-for-a-comfortable-night-s-sleep">The ASX share for a comfortable night's sleep</h3>



<p class="wp-block-paragraph"><strong>MF: </strong>If the market closed tomorrow for four years, which stock would you want to hold?</p>



<p class="wp-block-paragraph"><strong>TL:</strong> <strong>Proteomics International Laboratories Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-piq/">ASX: PIQ</a>).</p>



<p class="wp-block-paragraph">I just think <a href="https://www.fool.com.au/2022/07/27/2-outstanding-small-cap-asx-shares-that-could-explode-expert/">from a biotech, it's got everything going for it</a>. It's already had a test that's proven it's now a sales exercise. They do have the upcoming pipeline and yeah, that's the one.</p>



<p class="wp-block-paragraph">There is another one, but you only want one don't you?</p>



<p class="wp-block-paragraph"><strong>MF:</strong> By all means, please tell us.</p>



<p class="wp-block-paragraph"><strong>TL:</strong> From a mining perspective, I think <strong>Aurumin Ltd </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-aun/">ASX: AUN</a>).</p>



<p class="wp-block-paragraph">That's a gold company with ex-key personnel from <strong>Northern Star Resources Ltd </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-nst/">ASX: NST</a>). They have purchased the sandstone project. It's about a 794,000 ounce resource.&nbsp;</p>



<p class="wp-block-paragraph">So they purchased a gold resource. They're looking to grow through exploration and/or acquisition. The company share price has been punished due to drilling for lithium which failed to deliver significant results, combined with tax loss selling.&nbsp;</p>



<p class="wp-block-paragraph">I back management to undergo a decent growth profile in those four years. They're currently undergoing a 15 cent rights issue on a one-for-seven basis with a one-for-one, 25 cent option for existing shareholders.</p>



<p class="wp-block-paragraph">So I think the company has undergone some issues recently and I think these can be overcome, and I'd certainly back [the] management team to deliver.&nbsp;</p>



<p class="wp-block-paragraph">And one of the key aspects, I think, with any gold company that's looking to grow, sometimes you need to set the weakness to look at picking up assets that the majors don't want, and that's how Northern Star was built.</p>



<p class="wp-block-paragraph">[Northern Star] was a s***ty one-cent company that went to about $15, but during the time that Northern Star grew, the Australian gold index lost two-thirds of its value.</p>



<h3 class="wp-block-heading" id="h-looking-back">Looking back</h3>



<p class="wp-block-paragraph"><strong>MF: </strong>Is there a move that you regret from the past? For example, a missed opportunity or buying a stock at the wrong timing or price.</p>



<p class="wp-block-paragraph"><strong>TL: </strong>Oh, I regret not being more aggressive with selling.</p>



<p class="wp-block-paragraph">I think once you start seeing multiples, we all get delusions of grandeur and the dopamine levels increase and we think that the stock's going to continue running. But history has shown that you need to take profits along the way. </p>



<p class="wp-block-paragraph">You need to work out if your company would be racing in the Golden Slipper or the Melbourne Cup.  Once you can classify your company, then you're going to take profits in better fashion. </p>



<p class="wp-block-paragraph">But I always have the regret that I should be more assertive, and assertive with my profit taking.</p>



<p class="wp-block-paragraph"><strong>MF:</strong> It's difficult for the human mind to figure out, isn't it, knowing when to sell? People find buying a lot easier than selling.</p>



<p class="wp-block-paragraph"><strong>TL:</strong> Oh, geez, yeah, yeah, yeah. I've had stuff that's gone 10, 20 times, and a lot of clients won't sell because they think it's going higher. Then I try to get them to sell, and then&#8230; Yeah.&nbsp;</p>



<p class="wp-block-paragraph">But I guess in my sector of the market, they're exposed to abnormal gains that you wouldn't get in more conservative stocks.</p>
<p>The post <a href="https://www.fool.com.au/2022/07/28/richest-pipeline-in-asx-expert-names-3-small-cap-shares-to-buy/">&#039;Richest pipeline&#039; in ASX: Expert names 3 small-cap shares to buy</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                    </channel>
</rss>
